[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Medtronic\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":131},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,53,83,108],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100172884","product-surveillance-registry-100172884",false,"NCT01524276","Product Surveillance Registry","Medtronic Product Surveillance Registry","PSR","Inclusion Criteria:\n\n* Patient or legally authorized representative provides written authorization and\u002For consent per institution and geographical requirements\n* Patient has or is intended to receive or be treated with an eligible Medtronic product\n* Patient within enrollment window relative to therapy initiation or meets criteria for retrospective enrollment\n\nExclusion Criteria:\n\n* Patient who is, or will be, inaccessible for follow-up\n* Patient with exclusion criteria required by local law\n* Patient is currently enrolled in or plans to enroll in any concurrent drug and\u002For device study that may confound results","ALL",{"count":19,"type":20},100000,"ESTIMATED","OBSERVATIONAL","The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products. The Registry data is intended to benefit and support interests of patients, hospitals, clinicians, regulatory bodies, payers, and industry by streamlining the clinical surveillance process and facilitating leading edge performance assessment via the least burdensome approach.",[24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39],"Cardiac Rhythm Disorders","Urological Disorders","Neurological Disorders","Cardiovascular Disorders","Digestive Disorders","Intracranial Aneurysm","Mechanical Circulatory Support","Respiratory Therapy","Aortic, Peripheral Vascular and Venous Disorders","Minimally Invasive Surgical Procedures","Diagnostic Techniques and Procedures","Surgical Procedures, Operative","Renal Insufficiency","Neurovascular","Coronary Artery Disease","Ear, Nose and Throat Disorder","RECRUITING","2026-06-15",{"date":43,"type":44},"2026-06-17","ACTUAL",{"date":46,"type":4},"2012-01",{"date":48,"type":20},"2040-01",{"name":50,"class":51},"Medtronic","INDUSTRY",395,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":63,"conditions":64,"keywords":69,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},"100078039","product-performance-report-evaluate-long-term-reliability--performance-of-medtronic-marketed-cardiac-therapy-products-100078039","NCT00271180","Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products","Medtronic CRDM Product Performance Report","PPR","Subjects who meet the following inclusion criteria and do not meet any of the following exclusion criteria are eligible for enrollment.\n\nInclusion Criteria:\n\n• Subject or appropriate legal guardians provide written informed consent and\u002For authorization for access to and use of health information as required by an institution's IRB\u002FMEC\u002FREB\n\nAND one of the following must also apply:\n\n* Subject is indicated for implant or within 30 days post-implant of at least one Medtronic market-released product used for a pacing, sensing or defibrillation application\n* Subjects who participated in a qualifying study (IDE) of a Medtronic market-released product with complete implant and follow-up data and subject or appropriate legal guardian authorizes release of subject study data\n\nExclusion Criteria:\n\n* Subjects who are, or will be inaccessible for follow-up\n* Subjects with exclusion criteria required by local law (EMEA only)\n* Subjects receiving an implant of a Medtronic device at a non-participating center and the implant data and current status cannot be confirmed within 30 days after implant\n* Subjects implanted with a Medtronic device whose predetermined enrollment limit for that specific product has been exceeded",{"count":62,"type":20},20000,"The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.",[65,66,67,68],"Arrhythmia","Bradycardia","Heart Failure","Sinus Tachycardia",[70,71,72,73],"Cardiac Pacing","Implantable Cardioverter Defibrillator","pacemaker","Sinus Bradycardia","2026-05-05",{"date":76,"type":44},"2026-05-07",{"date":78,"type":44},"1983-01",{"date":80,"type":20},"2040-12",{"name":50,"class":51},320,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":91,"maxAge":4,"enrollmentInfo":92,"targetDuration":94,"studyType":21,"phases":4,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},"100631956","post-market-evaluation-of-real-world-outcomes-and-durability-to-support-implantable-inceptiv-spinal-cord-stimulation-therapy-100631956","NCT07507422","Post Market Evaluation of Real World Outcomes and Durability to Support Implantable Inceptiv™ Spinal Cord Stimulation Therapy","Post Market Evaluation of Real World Outcomes and Durability to Support Implantable SCS Therapy (PERSIST) Addendum - Inceptiv™ Spinal Cord Stimulation (SCS) Therapy","PERSIST","Inclusion Criteria:\n\n1. 18 years of age or older\n2. Patient must be SCS therapy naïve\n3. A clinical decision was made for the patient to receive an Inceptiv™ SCS system (pending satisfactory results from a Medtronic SCS trial) limited to on-label leads based on the specific geography for an on-label indication prior to enrollment in the study.\n4. Patient is on stable opioid dosage for 3 months prior to enrollment, if applicable\n5. Pain intensity of ≥ 6 as measured using the NPRS (0-10) in the predominant area(s) of pain that SCS is intended to treat\n6. Patient must have an on-label indication specific to geography.\n\n   * NOTE: Patients may be enrolled if they have upper limb radicular limb pain, related or unrelated to spine surgery\n   * NOTE: In the US, patients experiencing chronic back pain without a history of spine surgery and not eligible for spine surgery are on-label candidates for SCS if the pain is associated with degenerative disc disease, herniated disc, or radicular pain syndrome. Radicular pain syndrome (with or without prior spine surgery) is an approved indication for SCS implant.\n7. Diagnosis of chronic back and\u002For limb pain for an on-label indication lasting at least six months.\n\nExclusion Criteria:\n\n1. Has any existing or is planning to have a new active implantable neuromodulation device or system during the 5 year follow up period (e.g., peripheral nerve stimulation, sacral neuromodulation, intrathecal drug delivery system, a second SCS system)\n2. Has a complex pain pattern that involves both upper and lower limbs or back and upper limb\n3. Has a planned major medical procedure within 6 months before enrollment or after implant that may interfere with study results or confound results as determined by the Investigator\n4. Has a planned interventional procedure within 6 weeks (+\u002F- 2 weeks) before enrollment or after implant that may interfere with study results or confound results as determined by the Investigator\n5. Major untreated or unstable psychiatric comorbidity, such as suicidal ideations, personality disorders, schizophrenia etc., that could interfere with accurate pain reporting, study procedures, and\u002For confound evaluation of study, as determined by the Investigator\n6. Subjects with PCS total score \\>30 are not eligible unless ALL of the following are met:\n\n   1. Absence of uncontrolled major psychiatric disorder or active suicidality based on clinical evaluation.\n   2. Investigator documentation of adequate understanding of therapy, realistic expectations, and anticipated compliance with protocol follow-up\n7. Major non-indicated, untreated or refractory progressive disease (e.g., neurodegenerative disease {not including Diabetic Peripheral Neuropathy}, heart failure, cancer, osteoarthritis, fibromyalgia, chronic fatigue syndrome), or injury (e.g., fall resulting in hip fracture) that could interfere with accurate pain reporting, study procedures, and\u002For confound evaluation of study as determined by the Investigator\n8. Has inpatient or outpatient admissions for drug or alcohol dependency within past 12 months or current\u002Fongoing substance abuse\n9. Has a current prescription of ≥90 morphine milligram equivalents (MME) per day\n10. Has predominant mechanical back pain arising from facet or sacroiliac joint pain as the main cause of chronic low-back pain if low-back pain is the predominant pain condition, as determined by the Investigator\n11. Has mechanical spine instability (eg. Spondylolisthesis grade 2) as determined by the Investigator\n12. Has an active systemic or local infection that would delay trial or implant\n13. Is pregnant or planning on becoming pregnant\n14. Has a life expectancy of less than 1 year\n15. Involved in an injury claim, under current litigation, beneficiary of an injury claim, receiving worker's compensation, or planning any future litigation\n16. Has a condition that the Investigator determines would significantly increase perioperative risk (e.g., unstable or severe cardiac disease, liver disease, uncontrolled diabetes, kidney disease)\n\nPatients enrolled into the study with Diabetic Peripheral Neuropathy, Complex Regional Pain Syndrome and Upper Limb pain are required to meet further inclusion\u002Fexclusion criteria in order to contribute to the analysis for that particular condition. These criteria are designed to ensure that the patient's condition aligns with the standard diagnostic criteria set by applicable clinical guidelines.\n\nPainful Diabetic Peripheral Neuropathy (DPN) Inclusion Criteria\n\n* Clinical diagnosis of diabetes mellitus according to the American Diabetes Association guidelines (ADA).\n* Predominant pain condition being treated by SCS is lower-limb pain due to DPN\n* Hemoglobin A1c (HbA1c) must be \\\u003C8% within 6 months of enrollment for inclusion or have completed a preoperative risk assessment if \\>8%\n* Presence of either numbness or at least one sensory disturbance (e.g., increased or decreased sensitivity, burning, pricking\u002Fstabbing, aching, \"pins and needle\" sensation) in the foot\u002Ffeet.\n\nPainful DPN Exclusion Criteria\n\n* Lower-limb pain not associated with DPN or that cannot be distinguished from DPN (e.g., mononeuropathies, proximal neuropathies, nonneuropathic pain, peripheral vascular disease)\n* History of lower-limb amputation or planned lower-limb amputations due to diabetes\n* Large (≥3cm) and\u002For gangrenous ulcers or active infection of the lower limbs\n\nComplex Regional Pain Syndrome (CRPS) Inclusion Criteria\n\n* Meets diagnostic criteria for CRPS (International Association for the Study of Pain \"Budapest Criteria\")\n* Disease that is clinically restricted to one hand or foot and affects the entire hand, foot or lower extremity\n* CRPS is the predominant pain condition that SCS is intended to treat\n\nCRPS Exclusion Criteria\n\n* Presence of Reynaud's disease\n* Current or previous neurologic abnormalities unrelated to CRPS\n* Another condition affecting the function of the diseased or contralateral extremity\n* Dystonia as a predominant component of their presentation\n\nUpper Limb Pain (ULP) - non CRPS Inclusion Criteria\n\n* Be diagnosed with radicular pain syndrome, or be diagnosed with radicular pain secondary to failed back surgery or herniated disk\n\nULP - non CRPS Exclusion Criteria\n\n* Has significant cervical stenosis, as determined by the Investigator\n* Failed treatments of carpal tunnel syndrome and\u002For cubital tunnel syndrome\n* Has mechanical neck pain (e.g., facet spondylosis), as determined by the Investigator\n* Any previous history of surgery on the posterior elements (laminectomy, posterior fusion) of the cervical spine\n* Has brachial plexus injury as predominant cause of pain","18 Years",{"count":93,"type":20},970,"5 Years","The PERSIST study is being conducted within Medtronic's active post-market surveillance platform, the Product Surveillance Registry (PSR). The purpose of PERSIST is to generate long-term evidence for the Inceptiv™ Spinal Cord Stimulation therapy.",[97,98],"Chronic Pain","Intractable Pain","2026-04-28",{"date":101,"type":44},"2026-05-04",{"date":103,"type":44},"2026-04-17",{"date":105,"type":20},"2034-01-11",{"name":50,"class":51},3,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":91,"maxAge":4,"enrollmentInfo":114,"targetDuration":116,"studyType":21,"phases":4,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":130},"100634976","propel-drug-eluting-sinus-implant-family-ibuki-cohort-100634976","NCT07546682","Propel Drug-Eluting Sinus Implant Family IBUKI Cohort","Inclusion Criteria:\n\n* Patient or legally authorized representative (LAR) provides authorization and\u002For consent per institution and geographical requirements\n\n  * Patient has, or is intended to receive or be treated with, an eligible Medtronic product\n  * Patient is consented within the enrollment window of the therapy received, as applicable\n  * Patient has a confirmed diagnosis of CRS, and is indicated for FESS per Japan standard practice\n  * FESS is successfully completed without the occurrence of major\u002Fsignificant complications that may confound study results\n  * Successful placement of 2 to 4 corticosteroid-eluting implants in the ethmoid or frontal sinus (1 implant per sinus) in accordance with implant IFUs\n  * NOVAPAK is the only hemostatic packing material placed bilaterally in ethmoid sinuses\n\nExclusion Criteria:\n\n* Patient has clinical evidence of disease or a condition expected to compromise survival or ability to complete follow-up assessments through Month 6 (end of study)\n\n  * Participation is excluded by local law\n  * Patient is currently enrolled in, or plans to enroll in, any concurrent study that may confound the PSR results (i.e., no required intervention that could affect interpretation of all-around product safety and\u002For effectiveness)\n  * Patient has received biologic medication approved for the treatment of CRSwNP (e.g., dupilumab, mepolizumab) in ≤ 12 weeks prior to the baseline\u002Fprocedure visit\n  * Patient is contraindicated in accordance with IFUs of PROPEL family implants and\u002For NOVAPAK",{"count":115,"type":20},100,"6 Months","To confirm clinical safety and performance for the PROPEL family of products when used according to IFUs and standard of care in Japan.",[119],"Chronic Rhinosinusitis (CRS)",[121],"Chronic Rhinosinusitis, corticosteroid-eluting sinus implants, 22- item sinonasal outcome test","2026-04-16",{"date":124,"type":44},"2026-04-23",{"date":126,"type":20},"2026-04",{"date":128,"type":20},"2027-08",{"name":50,"class":51},1,""]